Robert J.  Coury net worth and biography

Robert Coury Biography and Net Worth

Chairman of Viatris
Robert J. Coury is the executive chairman of Viatris. He leads the board of directors, oversees the strategic direction of the company in collaboration with executive management, and advises the management team as they execute on the company’s strategy to drive value creation, while also ensuring robust board engagement with shareholders and other key stakeholders, among other responsibilities.

Coury most recently served as executive chairman of Mylan, where his strategic vision and tactical judgment led to the creation of a strong foundation for Viatris. Under Coury’s leadership at Mylan, the company went from being the third-largest generics pharmaceutical company in the U.S. to one of the largest pharmaceutical companies in the world, earning spots in both the S&P 500 and, prior to the company’s reincorporation outside of the U.S. in 2015, the Fortune 500.

During his time with Mylan, Coury led the company through a significant period of organic growth as well as a series of transactions totaling approximately $25 billion since 2007, transforming Mylan into a global powerhouse in the highly competitive pharmaceutical industry. This period of expansion resulted in his final transaction with Mylan, the completion of the approximately $27 billion combination with Pfizer’s Upjohn business to create Viatris, a new and distinctive global pharmaceutical player designed to deliver more efficient access to high quality medications for patients and healthcare systems around the world.

Coury was first elected to Mylan’s board of directors in February 2002, having served since 1995 as a strategic adviser to the company. He became the board’s vice chairman shortly after his election and served as chief executive officer from September 2002 until January 2012. He then served as executive chairman from 2012 until he became chairman in June 2016. The Mylan board reappointed Coury as executive chairman in April 2020.

Coury is the founder and president of the Robert J. Coury Family Foundation, which is a private foundation formed to help support his philanthropic efforts and his mission of giving back. He has served as a member of the University of Southern California President's Leadership Council since 2014.

What is Robert J. Coury's net worth?

The estimated net worth of Robert J. Coury is at least $11.31 million as of August 2nd, 2019. Mr. Coury owns 947,194 shares of Viatris stock worth more than $11,309,496 as of March 29th. This net worth evaluation does not reflect any other investments that Mr. Coury may own. Learn More about Robert J. Coury's net worth.

How do I contact Robert J. Coury?

The corporate mailing address for Mr. Coury and other Viatris executives is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. Viatris can also be reached via phone at (724) 514-1800 and via email at [email protected]. Learn More on Robert J. Coury's contact information.

Has Robert J. Coury been buying or selling shares of Viatris?

Robert J. Coury has not been actively trading shares of Viatris during the past quarter. Most recently, Robert J. Coury sold 250,000 shares of the business's stock in a transaction on Friday, March 11th. The shares were sold at an average price of $10.07, for a transaction totalling $2,517,500.00. Learn More on Robert J. Coury's trading history.

Who are Viatris' active insiders?

Viatris' insider roster includes W. Cornwell (Director), Robert Coury (Chairman), Michael Goettler (CEO), James Kilts (Director), Menassie Taddese (insider), and Pauline van der Meer Morh (Director). Learn More on Viatris' active insiders.

Are insiders buying or selling shares of Viatris?

During the last twelve months, insiders at the sold shares 8 times. They sold a total of 325,290 shares worth more than $3,901,932.18. The most recent insider tranaction occured on March, 13th when insider Anthony Mauro sold 250,000 shares worth more than $3,022,500.00. Insiders at Viatris own 0.3% of the company. Learn More about insider trades at Viatris.

Information on this page was last updated on 3/13/2024.

Robert J. Coury Insider Trading History at Viatris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2022Sell250,000$10.07$2,517,500.00View SEC Filing Icon  
3/9/2022Sell250,000$10.28$2,570,000.00View SEC Filing Icon  
See Full Table

Robert J. Coury Buying and Selling Activity at Viatris

This chart shows Robert J Coury's buying and selling at Viatris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Viatris Company Overview

Viatris logo
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Read More

Today's Range

Now: $11.94
Low: $11.78
High: $12.02

50 Day Range

MA: $12.16
Low: $11.40
High: $13.53

2 Week Range

Now: $11.94
Low: $8.74
High: $13.62

Volume

11,959,942 shs

Average Volume

10,295,994 shs

Market Capitalization

$14.32 billion

P/E Ratio

298.50

Dividend Yield

4.14%

Beta

1.14